Novotech is Asia’s leading independent full service contract research organisation (CRO). Novotech’s core business is to provide outsourced clinical trial management services to US and European biotech and pharmaceutical companies. These services include feasibility, trial regulatory and ethics approval, investigator and site management, and ensuring compliance with highly prescriptive trial protocols and regulations. Novotech manages the Australian and Asian elements, providing its customers with access to one of the world’s largest and fastest growing healthcare markets. Novotech currently employs 300 staff across a network of 14 offices in 12 countries.

Novotech was acquired by TPG Capital in September 2017.